Get the Stockscreener App
1.86
6.29%
0.11
After Hours:
1.89
0.03
+1.61%
Gain Therapeutics Inc stock is traded at $1.86, with a volume of 394.87K.
It is up +6.29% in the last 24 hours and up +6.29% over the past month.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
See More
Previous Close:
$1.75
Open:
$1.79
24h Volume:
394.87K
Relative Volume:
0.48
Market Cap:
$79.34M
Revenue:
$55,200
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.1606
EPS:
-0.5885
Net Cash Flow:
$-19.37M
1W Performance:
+14.11%
1M Performance:
+6.29%
6M Performance:
-9.71%
1Y Performance:
+10.06%
1-Day Range:
$1.769
$1.89
1-Week Range:
$1.63
$1.89
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.86 | 74.64M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GANX|Gain Therapeutics Inc|Price:1.750|Chg%:-0.070 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Gain Therapeutics Extends Cash Runway Into 2027 Operations - TipRanks
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO - Moomoo
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com - Investing.com South Africa
Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans - TradingView
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 - Investing.com
Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027 - Stock Titan
Gain Therapeutics advances Parkinson's drug rex... - Pluang
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - marketscreener.com
Gain Therapeutics Reports 81% Biomarker Drop in Some Patients - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Gain Therapeutics (GANX) Q1 2026 earnings summary - Quartr
Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary - Quartr
Gain Therapeutics (GANX) Proxy filing Summary - Quartr
Gain Therapeutics (GANX) Q4 2025 earnings summary - Quartr
GANX Q1 2026 Earnings: Narrower Loss Per Share Beats Estimates Amid Pre-Revenue PhaseQuarterly Financial Update - dars.gov.et
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - BioBuzz
With new FDA green light for developer, Parkinson’s clinical trial to launch soon - Parkinson's News Today
Gain Therapeutics Inc. (GANX) Declines Sharply as Key Support Level Comes into FocusElliott Wave Count - dars.gov.et
Gain Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares DeclineGuidance Update - dars.gov.et
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Good GAIN - Moomoo
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics Price Target Maintained With a $5.00/Share by BTIG - Moomoo
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Gain Therapeutics (GANX) Jumps 13% to $1.98 – Support and Resistance Levels in FocusPSAR Stop - dars.gov.et
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):